|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charlotte Dunne, PhD, Katrin Radloff, PhD, and Leonidas Gkionis, PhD, review the PTXΔLNP platform and how it offers a synergistic sister technology to the mRNA platform to obtain potent mRNA-LNPs for therapeutic applications.
|
|
|
Vince Antle, PhD, James Pipkin, PhD, and Lian Rajewski, PhD, say with decades of experience, proven safety, and recent and forthcoming authorizations in several new routes of delivery, the Captisol Team is looking forward to the next 2 decades and more of new drug products, new applications, and continued improvement in the technology.
|
|
|
Jim Huang, PhD, and Shaukat Ali, PhD, shed light on the design and formation of cubosomes with special focus on their applications for delivery of hydrophobic and hydrophilic small and large molecules, including oncology drugs and polynucleotides (DNA, mRNA, and siRNA).
|
|
|
Samir Acharya, PhD, Rajiv Vaidya, PhD, Laura Kerepesi, PhD, and Cyrill Kellerhals, MBA, provide their unique insights as they explore the challenges cell and gene therapy developers and manufacturers are currently facing, those they can expect to see in the future, and more critically, how to overcome them.
|
|
|
|
|
|
|
|
|

Labcorp provides industry leading preclinical medical device and combination product testing, as well as consulting and risk assessment solutions to help support you and your device from the earliest stages of study design to GLP assessments. With over 40 years of experience, our 150+ dedicated and highly experienced specialists have deep knowledge of delivering comprehensive preclinical testing, along with regulatory and compliance guidance that will provide you the answers, clarity, and confidence required to accelerate the development of your device or product. Click here for more.
|
|
|
|
|
|
 |
|
Global licensing and research collaboration to focus on discovery, development and commercialization of up to five cardiovascular targets leveraging Avidity’s proprietary AOC platform technology….
|
|
 |
|
Biodexa Pharmaceuticals PLC recently announced it has entered into an agreement for the assignment of Adhera Therapeutics, Inc.’s rights to tolimidone (formerly coded MLR-1023) under an exclusive,….
|
|
 |
|
Zevra Therapeutics, Inc. recently announced the completion of its acquisition of Acer Therapeutics Inc., which marks a significant step forward in executing Zevra’s strategy to become….
|
|
 |
|
Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, has recently announced it has acquired ExtremoChem Lda (ExtremoChem), an innovative start-up company focused on….
|
|
|
|
|
|
|
|
 |
|
This webinar will discuss some of the key trends from these leaders in the topical market on both a global and regional level, including the increased importance of sensory properties and the rise in non-conventional product formats, among others…..
|
|
 |
|
Intensified upstream bioprocesses are being developed to increase productivity while reducing footprint, costs, and timelines for manufacturing. The higher cell densities generated by….
|
|
|
|
|
|
|
|
 |
|
By the time your API is brought to a contract manufacturing organization (CMO), you have already put extensive amounts of resources into developing it. It becomes essential that you optimize your API supply chain to be aware of potential risks …
|
|
 |
|
Honeywell Aclar® thermoformable film enables pharmaceutical and medical device companies to achieve their sustainability commitments.
Aclar® film not only delivers a high moisture barrier to protect medicines, but it also reduces pack size, reduces waste, and reduces carbon emissions, compared …
|
|
 |
|
By: Dr. Bahar Yeniad and Dr. Pieter van Delft
Experts in copolymer microstructures have an important role to play in selecting biomaterials that can deliver desired performance of (bio)medical products. But how does microstructure link to the rate of API …
|
|
 |
|
Direct compression is often used for tablet manufacturing because it is the shortest, most effective, and least complex method. The physical properties of active pharmaceutical ingredients (APIs) can, however, create a challenge for flowability and compressibility, and, as a result, …
|
|
|
|
|
Upcoming eNewsletter Features:
December 6 – Bioavailability
December 13 – Inhalation Delivery
|
|
|
|
|
|
|
|